Zhejiang Jasan Holding Group Co Ltd

Jiansheng Group released its 2026 interim report, with net profit attributable to the parent company at 175 million yuan, an increase of 23.23% over the same period last year. Total operating revenue was 1.211 billion yuan, up 3.40% year-on-year, marking three consecutive years of growth. Net cash inflow from operating activities was 114 million yuan, down 54.94% year-on-year. The latest asset-liability ratio stands at 42.93%, gross margin at 30.46%, ROE at 7.80%, and diluted earnings per share at 0.53 yuan.

According to statistics from Securities Times Data Treasure, a total of 13 companies released their 2026 semi-annual reports on August 4. Among them, Jinyu Bio posted the largest profit increase, with net profit up 72.28 percent year-on-year. Jinyu Bio achieved net profit of 104 million yuan and operating revenue of 756 million yuan, up 22.09 percent. WuXi AppTec reported net profit of 11.08 billion yuan, up 29.43 percent, on operating revenue of 28.897 billion yuan, up 38.93 percent. Companies such as Jasan Group, Sinocare, Sihui Fushi, and Wanda Bearing also recorded net profit growth, while seven companies including Jiahuan Technology and Sinodata saw net profit decline year-on-year.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.